NCT01237951 · OUTCOME

Progression-free Survival (PFS)

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma · Source last updated 2020-05-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: From date of transplant until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.

What was measured

Number of participants remain free of progression or death after ASCT

Patients with refractory or relapsed myeloma received high-dose GemBuMel with ASCT

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Gemcitabine/Busulfan/Melphalan	74

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Gemcitabine/Busulfan/Melphalan	31	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Number of participants remain free of progression or death after ASCT

groups

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

From date of transplant until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.

title

Progression-free Survival (PFS)

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice